Myopia Clinical Trial - Efficacy & Safety of 1% Atropine "5+3" Regimen in

Status Recruiting

Clinical Trial Summary

Studies have shown that atropine eye drops are effective in controlling myopia in children and adolescents. 1% atropine ophthalmic drug has obvious curative effect for controlling myopia, but its side effects such as photophobia and blurred vision limit its popularization and use. In the early stage, our research group used 1% atropine "5+3" myopia control program and 1% atropine alternate eye myopia control program. Retrospective clinical research data showed that it could significantly reduce side effects and improve use compliance, but there is currently no evidence from prospective clinical studies.

Clinical Trial Description

Studies have shown that atropine eye drops are effective in controlling myopia in children and adolescents. Among them, low-concentration atropine has few side effects and is the primary recommendation, but many clinical practices and studies suggest that its effect in controlling myopia is limited. 1% atropine ophthalmic drug has obvious curative effect advantages in controlling myopia, but its side effects such as photophobia and blurred vision limit its popularization and use. In the early stage, our research group used 1% atropine "5+3" myopia control (eye instillation for 5 consecutive nights in the first week of each month, one night per week in the 2nd, 3rd, and 4th weeks; after 3 months of monocular application, change to the contralateral eye), data from retrospective clinical studies have shown that it can significantly reduce side effects and improve compliance, but there is currently a lack of evidence from prospective clinical studies. Therefore, this study intends to use a randomized controlled trial, with 1% atropine used in both eyes once a week as the control group, to evaluate the effect of the "5+3" regimen in controlling myopia (spherical equivalent and axial length), safety (accommodation amplitude, amount of phoria, binocular vision function, etc.), and the compliance and side effects (photophobia, blurred vision, etc.). ;

Study Design

Related Conditions & MeSH terms

Myopia

Clinical Trial Details

NCT number	NCT05448989
Study type	Interventional
Source	Shanghai Eye Disease Prevention and Treatment Center
Contact	Yan Xu, M.D.
Phone	+86 18621080996
Email	drxuyan_2004@163.com
Status	Recruiting
Phase	Phase 4
Start date	January 1, 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04923841` - Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine	N/A
Active, not recruiting	`NCT04080128` - Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control	N/A
Active, not recruiting	`NCT05275959` - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)	N/A
Completed	`NCT04604405` - Effects of 650nm Low Energy Light on Human Retina and Choroid Microcirculation	N/A
Recruiting	`NCT05594719` - The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow	N/A
Completed	`NCT05594732` - The Effects of Different Outdoor Light Exposure Modes on Retinal Blood Flow	N/A
Completed	`NCT04492397` - Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI)	N/A
Completed	`NCT04536571` - Vision Stability and Preference for Soft Toric vs. Soft Spherical Contact Lenses	N/A
Completed	`NCT06046209` - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens	N/A
Recruiting	`NCT06344572` - Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia	Phase 3
Recruiting	`NCT05611294` - Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction	N/A
Completed	`NCT05656885` - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses	N/A
Active, not recruiting	`NCT05534022` - Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.	N/A
Completed	`NCT03934788` - the Clinical Performance of the Oxysoft Daily Disposable Silicone Hydrogel Soft Contact Lens	N/A
Completed	`NCT03701516` - Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2	N/A
Completed	`NCT05538754` - Post-Market Evaluation of the EVO ICL	N/A
Completed	`NCT03139201` - Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens	N/A
Completed	`NCT02555722` - Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear	N/A
Not yet recruiting	`NCT06009458` - Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear	N/A
Recruiting	`NCT05548478` - Corneal Endothelial Cell Injury Induced by Mitomycin-C	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms